Hypertension genomics and cardiovascular prevention

Fu Liang Ng¹², Helen R. Warren¹, Mark J. Caulfield¹²

¹William Harvey Research Institute, The NIHR Biomedical Research Centre at Barts, Queen Mary University London, London, UK; ²Barts BP Centre of Excellence, Barts Heart Centre, The NIHR Biomedical Research Centre at Barts, St Bartholomew’s Hospital, W Smithfield, London, UK

Contributions: (I) Conception and design: All authors; (II) Administrative support: None; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: FL Ng; (V) Data analysis and interpretation: FL Ng; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Dr. Fu Liang Ng. Barts William Harvey Research Institute, The NIHR Biomedical Research Centre at Barts, Charterhouse Square, Queen Mary University London, London EC1M 6BQ, UK. Email: f.ng@qmul.ac.uk.

Abstract: Hypertension continues to be a major risk factor for global mortality, and recent genome-wide association studies (GWAS) have expanded in size, leading to the identification of further genetic loci influencing blood pressure. In light of the new knowledge from the largest cardiovascular GWAS to date, we review the potential impact of genomics on discovering potential drug targets, risk stratification with genetic risk scores, drug selection with pharmacogenetics, and exploring insights provided by gene-environment interactions.

Keywords: Hypertension; cardiovascular disease; genetics; risk score; pharmacogenetics; gene-environment

Submitted Jun 05, 2018. Accepted for publication Jun 11, 2018.
doi: 10.21037/atm.2018.06.34
View this article at: http://dx.doi.org/10.21037/atm.2018.06.34

Introduction

Hypertension continues to be a major cause of worldwide mortality and morbidity (1), with genomics proposed to have the potential to assist in reducing the overall burden of cardiovascular events (2). The role of genomics has stretched from the initial discovery of monogenetic diseases with large effects (3), to large-population genome-wide association studies (GWAS) detecting common genetic variations with modest effect sizes. The recent publication of the largest cardiovascular genetic association study to date, with over 1 million participants, demonstrated the total number of genetic signals associated with hypertension surpassing 1000, at 901 genetic loci (4). Each subsequent GWAS iteration continues to increase our understanding of the genetic architecture of hypertension and cardiovascular disease. Here, we review the promise of translating genomics into clinical application through potential novel treatment options, risk scores, gene-environment interactions, or pharmacogenetics.

Blood pressure genomics

The vast information provided by large GWAS has resulted in greater understanding of the polygenic nature of blood pressure regulation, where numerous single nucleotide polymorphisms (SNPs) act additively to impact on cardiovascular disease. However, the translation into establishing the underlying genetic mechanism remains difficult. The key barrier is that the causal variant might not be readily identified by the lead GWAS SNP. Instead, the lead SNP indicates a chromosomal region where the causal gene may typically reside within a 500 kb genetic window, with other SNPs in high linkage disequilibrium (LD) (5). This window however only serves as broad guidance, with the increasing understanding of the 3-dimensional configuration of DNA as being important to genetic function, particularly with the discovery of various genomic regions with high levels of local chromatin interactions implicating longer-range interactions (6). Chromatin interaction Hi-C studies aim to identify long-range target genes of non-coding SNPs, and the recent
blood pressure GWAS has identified up to 484 long-range interactions, for example between the SLC30A10 locus and the TGFBR2 gene being 1.2 Mb apart (4). To compound this complexity, the potential for trans-acting regulatory elements (7) makes identifying the functional variant difficult to pinpoint. Furthermore, a significant proportion of GWAS-significant SNPs is intergenic or near genes without any obvious connection to cardiovascular disease.

To date, there has been some success in exploring the functional impact of these genetic variants. Perhaps the best example remains the UMOD (uromodulin) gene where the S’ SNP rs13333226 was identified as associated with hypertension in an early GWAS (8). Subsequently, UMOD-deficient mice demonstrated increased sequestration of the loop diuretic target sodium-potassium-chloride co-transporter 2 (NKCC2) in subapical vesicles together with reduced phosphorylation, both combining with resultant reduced co-transporter activity (9). Mimicking the effect of loop diuretics, this resulted in increased natriuresis and a 20 mmHg lower blood pressure in knockout mice. The BP difference was exacerbated with salt-loading, where the knockout mice were resistant to its hypertensive effects (10). Conversely, the blood pressure of UMOD transgenic mice were salt-sensitive (11).

More recent successes include exploring the genetic function of blood pressure loci, including NPR3 (12), SLC4A7 (13) and SLC39A8 (14). The BP-raising allele at the NPR3 (natriuretic peptide receptor C) locus was associated with altered chromatin interactions, increased NPR3 expression, linked to increased vascular smooth muscle cell proliferation, angiotensin II-induced calcium flux and cell contraction (12). Vascular smooth muscle has also been shown to be relevant to the SLC4A7 (electroneutral sodium-bicarbonate cotransporter 1) locus. The BP-raising allele was associated altered chromatin interactions, increased gene expression, elevated steady-state intracellular pH and accelerated recovery from intracellular acidosis, all independent of the missense polymorphism resulting in the amino acid substitution Glu326Lys (13). Vascular endothelial cells appear to have a greater influence with the SLC39A8 locus, encoding ZIP8, a heavy metal ion transporter. The blood pressure polymorphism is associated with an Ala391Thr variation where blood pressure raising variant Ala391 demonstrated a higher propensity to cadmium accumulation, increased ERK2 phosphorylation, NFkB activation, and reduced vascular endothelial cell viability (14).

With the increased number of genetic loci identified, experimental exploration of each individual locus becomes unfeasible. Despite these complexities, there is still hope that future therapeutic targets could be identified within these genetic loci. There has been a rapid expansion of bioinformatics tools that can assist in prioritising areas to optimise the use of resources to identify new therapeutic options. The process of investigating genetic variants can be assisted by in silico analysis, indicating loci with eQTLs in tissues of interest (e.g., GTEx, www.gtexportal.org), DNase I hypersensitivity sites (e.g., DeepSEA, http://deepsea.princeton.edu/), as well as a handful of nonsynonymous polymorphisms that have been predicted to be damaging (e.g., SIFT, http://sift.jcvi.org/; and PolyPhen, http://genetics.bwh.harvard.edu/pph2/). Druggability analyses have provided new genetic support for known anti-hypertensive targets (4), with genetic loci including targets of established antihypertensive medications such as SLC12A2 (loop diuretics), CACNA1C and CACNB4 (calcium channel blockers), within the pathway itself such as NOS3 (nitric oxide donors), targets under investigation EDN1 (endothelin 1), NPR1 and NPR3 (natriuretic peptide analogues), and ENPEP (aminopeptidase A inhibitors), or drugs with known antihypertensive effects that could allow for repurposing such as sodium-glucose co-transporter 2 inhibitors for diabetes mellitus (SLC5A1). This demonstrates, as a proof of concept, the capabilities of genetic studies. In other words, the ability to confirm genetic associations for genes that are the targets of current anti-hypertensive drug targets, then it provides hope that some of the other newly discovered genes for blood pressure may also have the potential to lead to new and improved drugs for hypertension in the future.

In silico functional analyses on gene expression have also highlighted the enrichment of genes relating most strongly to the vasculature, and to a lesser extent, adrenal and adipose tissue. From pathway analyses, there was also an enrichment of signals within the transforming growth factor-β (TGFβ) pathway (4), which is a pathway known to influence renal sodium handling and ventricular remodelling. Furthermore, plasma TGFβ levels have been correlated with hypertension (15). The genes implicated include the growth factor itself (TGFβ2), its receptors (TRFBR2 and TGFBR3), downstream signalling proteins such as the activin A receptor type 1C (ACVR1C) and bone morphogenetic protein 2 (BMP2), and transcription factors important in TGFβ signalling, such as Kruppel-like family 14 (KLF14) which regulates expression of TGFβ receptors (16). This might suggest members of this pathway...
In recent years, there has also been an increased interest in epigenomic-wide association studies (EWAS). Analogous to GWAS utilising SNPs, these studies utilise quantifiable epigenetic marks, typically DNA methylation, to identify loci that can discriminate between cases and controls (17). EWAS, combined with gene expression analyses have identified six genes (\textit{TSPAN2}, \textit{SLC7A11}, \textit{UNC93B1}, \textit{CPT1A}, \textit{PTMS}, and \textit{LPCAT3}) with mutual associations between methylation, gene expression, and blood pressure. These genes have hitherto not been implicated in the pathogenesis of hypertension with GWAS, indicating a distinct and cumulative gain of knowledge with from this complementary methodology (18). Like its genomic counterpart, EWAS too has limitations. Epigenetic variations may arise as either a cause or a consequence of disease, and can be difficult to differentiate without the use of expensive and time-consuming longitudinal cohort studies. In addition, samples currently utilised for EWAS are almost invariably blood, which may not reflect the unique epigenetic signature of the tissue of interest.

**Genomics of blood pressure and other cardiovascular risk factors**

In terms of prioritising research for potential future therapies, it may be reasonable to consider genetic loci that are signals across other cardiovascular risk factors in addition to hypertension, which often co-exist (Table 1) (4,19-24). These signals of interest include B-Cell CLL/lymphoma 2 (\textit{BCL2}), carbamoyl-phosphate synthase 1 (\textit{CPS1}) and melanin receptor 1B (\textit{MTNR1B}). The rs79598313/KDF1 (keratinocyte differentiation factor 1) locus is more complex as the genes within this LD block also includes AT-Rich Interaction domain 1A (\textit{ARID1A}), nuclear distribution c, dynein complex regulator (\textit{NUDC}) and zinc finger DHHC-type containing 18 (\textit{ZDHHC18}), where little is known of these gene products in relation to pathogenesis of hypertension. As there is a large body of evidence already on \textit{APOE} in cardiovascular research, this locus is not reviewed in detail here.

\textit{BCL2} is a known inhibitor of apoptosis (25), and is positioned within the angiotensin II-induced endothelial apoptosis pathway (26). However, it is unclear whether modulating \textit{BCL2} function has an impact on endothelial survival or function. \textit{BCL2} also has a role in a range of tissues, and its upregulation in numerous tumours has made it a potential cancer therapeutic target (27). With this, there is potential for off-target effects and may give reason to pause if considering \textit{BCL2} as an anti-hypertensive/diabetic therapy.

\textit{Carbamoyl-phosphate synthase 1 (CPS1)} catalyses the rate-limiting step in the urea cycle and L-citrulline production. Vascular endothelial cells synthesize...
endogenous L-arginine by recycling L-citrulline, the by-product of nitric oxide synthesis, using components of the urea cycle, potentially linking nitric oxide production and the urea cycle. There is already some support for CPS1 as a regulator of vascular tone, where the naturally occurring T1405N variation has been observed to influence forearm blood flow responses to bradykinin and nitroprusside, and levels of nitric oxide metabolites (28). There is less known about the biological link between CPS1 and HDL cholesterol, except that there the proteomic changes in murine adipose tissue following a high fat diet were primarily within the urea cycle, including CPS1 (29). There may be however concerns for off-target effects when modulating CPS1 activity. Expression data from GTEx suggests that CPS1 is predominantly expressed in the liver. Furthermore, CPS1 deficiency is a rare autosomal recessive inherited disease resulting in severe hyperammonaemia and protein intolerance (30).

**MTNR1B** encodes a high affinity receptor for melatonin (31), and appears to influence 24-hour non-rapid eye movement sleep (32). There is some epidemiological support for the influence of melatonin on circadian blood pressure (33), and melatonin reducing nocturnal BP in a small clinical trial (34). This discovery of a melatonin receptor as a genetic signal for blood pressure may provide further impetus to revisit melatonin as a therapeutic target. There is a larger body of evidence for MTNR1B in type II diabetes mellitus in terms of genetic/genomic analyses, clinical/epidemiology data, functional analyses of genetic polymorphisms, *in vitro* and animal model, where there are still controversies on the potential relationship (35).

### Genomics of blood pressure and other cardiovascular endpoints

An alternative aid prioritising genetic loci to undergo functional assessment would consider those that overlap with the genetic signals of cardiovascular endpoints. This approach is however limited by the heterogeneous pathophysiology of cardiovascular endpoints, particularly with heart failure, stroke and chronic renal disease. Furthermore, there is notable variation in classification of phenotypes within each cardiovascular endpoint (e.g., chronic kidney disease has also been investigated under phenotype classifications of end-stage renal failure, creatinine and kidney function decline). Another limitation is the lower prevalence of heart failure and stroke, and subsequently, a limited number of large GWAS (Table 2) (24,36-41).

Signals of association that overlap between blood pressure and coronary artery disease GWAS include apolipoprotein E (*APOE*), endothelin receptor type A (*EDNRA*) and SWAP Switching B-Cell Complex Subunit 70 (*SWAP70*). Overlapping GWAS signals for blood pressure and renal

---

**Table 2** Heterogeneity of classification, number/size of studies and populations/ ancestries of cardiovascular GWAS

<table>
<thead>
<tr>
<th>Traits</th>
<th>Number of studies</th>
<th>Approximate size of largest studies (discovery + replication combined)</th>
<th>Populations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type II diabetes</td>
<td>51*</td>
<td>40,000 cases, 160,000 controls (36)</td>
<td>Broad range—European, South Asian and East Asian ancestries</td>
</tr>
<tr>
<td>Lipids—Chol, HDL, LDL, lipoprotein</td>
<td>49</td>
<td>190,000 individuals (24)</td>
<td>Predominantly European, some East Asian ancestries</td>
</tr>
<tr>
<td>Ischaemic heart disease—myocardial infarction, coronary artery disease (combined endpoint)</td>
<td>9</td>
<td>75,000 cases, 260,000 controls [(37) CAD], 380,000 controls [(38) MI]</td>
<td>Predominantly European, some other ancestries in largest studies</td>
</tr>
<tr>
<td>Stroke—stroke, ischaemic stroke, small vessel or large artery stroke</td>
<td>13</td>
<td>25,000 cases, 90,000 controls (39)</td>
<td>Predominantly European</td>
</tr>
<tr>
<td>Chronic kidney disease—chronic kidney disease, ESRF (small samples), Creatinine and kidney function decline</td>
<td>8</td>
<td>90,000 individuals (40)</td>
<td>Predominantly European</td>
</tr>
<tr>
<td>Heart failure</td>
<td>2</td>
<td>22,000 individuals (41)</td>
<td>Predominantly European</td>
</tr>
</tbody>
</table>

Summary characteristics of GWAS studies as derived from GWAS catalog (https://www.ebi.ac.uk/gwas/). *, not including GWAS studies on “glycosylated haemoglobin A1c”. LDL, low density lipoprotein cholesterol; HDL, high density lipoprotein cholesterol.
function include vascular endothelial growth factor A (VEGFA) and the aforementioned carbamoyl-phosphate synthase 1 (CPS1) (Table 3) (4,37,38,40,42,43). The impact of apolipoprotein E and endothelin on cardiovascular disease has been well described and not discussed further in this review.

SWAP70 belongs to a family of proteins involved in an array of processes that control autoimmune phenotypes which spontaneously develop in their absence (44), where one of its homologues is associated with the development of systemic lupus erythematosus (SLE) (45). Autoimmune diseases are increasingly recognised as a risk factor for cardiovascular disease, with the latest cardiovascular risk calculator, QRISK3, having added SLE into the latest iteration (46). Most of the studies on SWAP70 thus far centre on immune cells. However, in context of Kaposi sarcomas, SWAP70 was found to be crucial for in vitro endothelial tube formation and endothelial sprouting (47). The relevance of this finding to endothelial cells in blood pressure regulation is unclear.

The presence of VEGFA on this list is not surprising due to the side effect profile of anti-VEGF cancer therapies with increased risk of hypertension, proteinuria and myocardial infarctions (48,49). The proposed mechanism would be via both vascular and renal endothelial cells, and podocytes. Reduced VEGF activity in the vascular endothelium could lead to vascular rarefaction and reduced nitric oxide availability. Within the kidneys, there could also be downregulation of tight junctions, resulting in proteinuria (48). The importance and opposing effect of VEGF in cancer pathways suggests that it is less likely to be a successful candidate target for cardiovascular disease.

It is also notable that the ABO gene (α-1,3-N-acetylgalactosaminyltransferase and α-1,3-galactosyltransferase), most commonly known for its influence on the ABO blood group, is a signal across multiple traits, including blood pressure (4), glycated haemoglobin A1c (50), hypercholesterolaemia (51), and ischaemic heart disease (52), but with various SNPs not in high LD. The ABO blood group has long been an established risk factor for arterial thrombosis (53), and a recent meta-analysis, the clinical phenotype of ABO blood group itself is a risk factor for coronary artery disease, where blood group A carried the highest risk, and lowest risk with blood group O (54). This may be in part related to the presence of N-linked oligosaccharide side chains on von Willebrand factor (vWF) molecules that contain A and B blood group antigens which in turn decreases von Willebrand factor clearance (55). Individuals with non-O (A, B, or AB) blood groups have 25% higher vWF levels than individuals with blood group O (56). There may also be a role for angiotensin converting enzyme

### Table 3 Overlapping signals between blood pressure and cardiovascular endpoint GWAS

<table>
<thead>
<tr>
<th>SNP</th>
<th>Gene (or nearest)</th>
<th>Associated trait</th>
<th>Expression</th>
<th>Arteries</th>
<th>Renal cortex</th>
<th>Adrenal</th>
<th>Highest expressing tissues</th>
</tr>
</thead>
<tbody>
<tr>
<td>rs7412 (missense)</td>
<td>APOE (apolipoprotein E)</td>
<td>PP (4) + CAD (37)</td>
<td>Moderate</td>
<td>Very high</td>
<td>Very high</td>
<td></td>
<td>Liver, adrenals</td>
</tr>
<tr>
<td>rs78049276/rs6841581* (upstream variant 2KB)</td>
<td>EDNRA (endothelin receptor type A)</td>
<td>PP (42) + CAD (37)</td>
<td>Moderate</td>
<td>Low</td>
<td>Low</td>
<td>Female reproductive organs, arteries</td>
<td></td>
</tr>
<tr>
<td>rs360153/rs10840293* (intrinsic)</td>
<td>SWAP70 (SWAP switching B-cell complex subunit 70)</td>
<td>DBP (4) + CAD (38)</td>
<td>Moderate</td>
<td>Low</td>
<td>Low</td>
<td>Adipose, tibial nerve, spleen</td>
<td></td>
</tr>
<tr>
<td>rs9472135 (intergenic)</td>
<td>VEGFA (vascular endothelial growth factor A)</td>
<td>DBP (4) + eGFR (43)</td>
<td>Moderate</td>
<td>Moderate</td>
<td>Moderate</td>
<td>Thyroid</td>
<td></td>
</tr>
<tr>
<td>rs1047891 (missense)</td>
<td>CPS1 (carbamoyl-phosphate synthase 1)</td>
<td>SBP (4) + eGFR (40)</td>
<td>Very low</td>
<td>Very low</td>
<td>Very low</td>
<td>Liver</td>
<td></td>
</tr>
</tbody>
</table>

Where multiple studies have identified the genome-wide association, the earlier study is quoted. Expression based on GTEx data, cut-off mean TPM (tags per million) set at minimal/undetectable <0.2; very low 0.2 to 2, low 2 to 20, moderate 20 to 100, high 100 to 1,000 and very high >1,000 for easier comparison. *, denotes SNPs which are in high LD across GWAS (and the SNPs are listed in order of blood pressure variant first); SBP, systolic blood pressure; DBP, diastolic blood pressure; PP, pulse pressure; CAD, composite outcome of coronary artery disease including myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chronic ischemic heart disease; eGFR, estimated glomerular filtration rate.
in this relationship between \( ABO \) and cardiovascular disease. Both the \( ABO \) genotype \((57,58)\) and blood group phenotype \((59)\) are associated with angiotensin-converting enzyme activity. This may in part provide the biological link with hypertension. The relationship between the \( ABO \) locus and type II diabetes and hypercholesterolaemia may lie with the link with pancreatic lipase levels varying with \( ABO \) genotype at GWAS-significance levels \((57)\), but this hypothesis still requires further study. Overall, this may suggest that \( \alpha\)-1,3-N-acetylgalactosaminyltransferase or \( \alpha\)-1,3-galactosyltransferase may be a possible therapeutic target, spanning multiple cardiovascular comorbidities.

**Genetic risk scores**

Outside of generating new pharmacological targets, a different route that genomics can potentially influence clinical care is via augmenting the predictive value of clinical risk scores. Clinical risk scores have long been in use to estimate the actual risk of developing a disease of a defined population, and that the absolute risk of cardiovascular disease is influenced by the combination of risk factors \((60,61)\). Likewise, even though each blood pressure-associated variant only has a small effect individually, a genetic risk score (GRS) can consider the larger aggregated effects of all combined variants. Clinical interventions (both pharmacological and lifestyle) can be effective in delaying the disease progression from prehypertension to hypertension, and the development of cardiovascular events, but also carries the risk of adverse events, as well as financial and opportunity costs. With this, improvements in prediction models to stratify patient populations according to risk would allow a precision medicines strategy to prevent future cardiovascular disease. Genetic risk scores aim to add to clinical risk scores to enhance its predictive value.

The combination of all known BP variants across 901 loci was associated with a 10.4 mmHg higher SBP, and an over three-fold sex-adjusted higher risk of hypertension (OR 3.34), and odds ratio of incident cardiovascular events of 1.52 comparing top-bottom GRS deciles \((4)\). This predictive ability of GRS highlights the potential to influence clinical management by improved risk stratification. However, this does not assess the utility of GRS in addition to current clinical risk scores. A study using only 22 blood pressure variants as part of a genetic risk score improved discrimination for incident hypertension on top of clinical risk factors, but only modestly (C-index change \(=0.3–0.5\%\)) \((62)\). While this only showed a modest change, it only utilised a small fraction of known loci and there is potential to improve the discriminatory power by using all the 901 known loci.

To assess the impact of genetics and exposure to lifestyle factors on blood pressure, a genetic risk score composed of 314 blood pressure loci was assessed together with a healthy lifestyle score (BMI, sedentary hours, alcohol intake, meat intake, urinary sodium excretion, fruit and vegetable intake, fish intake and smoking status). For all genetic risk score tertiles, a healthier lifestyle score is associated with lower blood pressure and improved outcomes \((63)\). A separate study focused on the impact of genetic influence on salt-sensitivity with participants undertaking specific dietary interventions of low-sodium, high-sodium and high-sodium/potassium-supplemented diets. Higher GRS conferred larger rises in blood pressure when exposed to a high-sodium diet, but a smaller blood pressure fall with a low-sodium diet. However, the overall influence of the GRS groups is far smaller than that of the dietary interventions itself \((64)\). Taken together, this emphasises that lifestyle management should be for the whole population, rather than targeted using genetic information.

There may however be utility for GRS within a “precision medicine” approach. An example could be seen in studies where GRS improved clinical risk score C-statistics of predictive coronary artery disease in the region of 0.4% to 1% \((65,66)\), utilising between 20 to 50 SNPs in these GRS. Importantly, this small SNP panel resulted in net reclassification by 5% to 9% \((66)\). The improved reclassification to influence the decision to initiate treatment with statins has numbers-needed-to-treat (NNTs) in the ranging between 20 and 60 s, being lower for those with the highest genetic risk \((66,67)\).

GRS has also been proposed as a potential motivator in adherence to lifelong pharmacological therapies and behavioural changes, particularly in use for counselling patients with those at higher risk categories. Adding GRS to standard-of-care in counselling patients with coronary artery disease may produce some benefits in changing behaviours. In randomised controlled trials, the additional knowledge of their GRS resulted in modest weight loss and increased physical activity \((68)\), and improvements in LDL-cholesterol \((69)\), but requires further evaluation particularly to consider whether it impacts on clinical end-points. This added GRS-based counselling could be important in translating into management of patients with resistant hypertension, where non-adherence to medications is known to be high \((70)\).
There is however other barriers before GRS reach clinical practice. While there may be some clinical benefit from GRS, it is well worth considering the cost implications of genotyping arrays, particularly as it would involve a large screening population, and in view of the potentially large NNTs. There should also be consideration of the potential ethical impact of such risk scoring and the potential to impact on day-to-day lives of the general population receiving genetic risk score results. At the time of this review, several countries have chosen not to adopt laws to specifically prohibit access to genetic data for purposes of life insurance. Several other countries have either adopted laws or developed voluntary moratoria with the industry to prevent this access (71). The impact would be regional, particularly as the perceptions and importance of life insurance varies from country-to-country, and within countries itself. There would also be the cost implications of providing the necessary counselling that should be provided together with such results.

Hypertension gene-environment (GxE) interaction studies

Another method of elucidating the impact of genetics on the pathogenesis of hypertension is through gene-environment (GxE) interaction studies. The model of GxE studies is based on the hypothesis that individuals may be more vulnerable to the negative effects of environmental adversity, or alternatively, more responsive to positive environmental experiences. GxE studies can also reveal further blood pressure-associated loci that can only be detected via an adjustment of, or interaction with, environmental exposure.

A productive region of GxE research thus far is with salt-sensitivity, where the GenSalt consortium identified up to 9 genetic loci interacting with dietary salt intake to influence blood pressure (72). Potential therapeutic targets that may arise from these findings is from the CASP4 (Caspase 4) and MAP kinase interacting serine/threonine kinase 1 (MNK1) loci. Caspase 4 is a protein in the cysteine-aspartic acid protease family that plays an import role in inflammation and innate immunity. The loss of proximal tubules and renal injury in nephropathic cystinosis appears to be associated with overexpression of the CASP4 gene (73). In view of the importance of renal sodium filtration and reabsorption, further studies on the potential role of CASP4 in salt-sensitivity may be warranted. MNK1 gene functions as a Ser/Thr protein kinase that interacts with ERK1 and p38 mitogen-activated protein kinase (MAPK) (74), a pathway that is involved in BP regulation through norepinephrine and angiotensin II (75). Its pathophysiological role in salt-sensitivity is unclear, but due to its position in a known blood pressure regulating pathway, may be an area of fruitful investigation.

Other gene-environment interactions for blood pressure identified so far include 15 genetic loci identified to interact with cigarette smoking to influence blood pressure (76). Additionally, solute carrier family 16 member 9 (SLC16A9, also known as monocarboxylic acid transporter 9) interacting with alcohol consumption (77), and transmembrane protein 182 (TMEM182) with body-mass index (78), where the biological relevance for both findings are currently uncertain.

Hypertension pharmacogenetics

Worldwide, optimal blood pressure management is achieved in fewer than 40% of those treated, despite the availability of a considerable number of drugs from different pharmacological classes (79). Although there are numerous contributing factors for this, one is the degree of genetic-based inter-subject variation in response to different pharmacological classes. Pharmacogenomics have been proposed to have the potential to identify genetic signals that could predict therapeutic effect or adverse outcomes for different drug classes (80). Currently, decisions on antihypertensive drug therapy selection may be based on age and ancestry (81-83), which in turn acts as a surrogate for plasma renin activity (84). It remains that any use of pharmacogenetics requires an increase in predictive value in addition to current clinical stratification.

While candidate gene studies are not particularly common in the current era of genome-wide studies, one of the strongest evidence for pharmacogenetics relates to the genetic locus at ADRB1 (β1-adrenoceptor) and the blood pressure response to β-blockers (85), which has also since been shown to impact on heart failure outcomes (86). As only very few genetic variants yielded pharmacogenetics effects individually, risk score models combining the effects of multiple polymorphisms have been investigated. For example, within the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study, using a risk score including SNPs within the FGF5, CHIC2, MOV10, and HFE genes, reveals a potential difference in response to β-blockers in the magnitude of 14/20 mmHg (P=3.3x10^-6 for SBP; P=1.6x10^-6 for DBP) comparing carriers of one vs.
Another candidate gene study was based on the knowledge renal tubular expression of epithelial Na⁺-channel (ENaC) which is known to be influenced by a functional neural precursor cell expressed, developmentally down-regulated 4-like, E3 ubiquitin protein ligase (NEDD4L) polymorphism. A subset of the NORDIL (Nordic Diltiazem) trial revealed a pharmacogenetics effect at rs4149601, where carriers of the variant associated with higher ENaC expression had a greater reduction in blood pressure for patients taking β-blocker or diuretic monotherapy but not the calcium channel blocker diltiazem (88). The genetic effect (around 4.5/1.5 mmHg) is, however, modest compared the overall therapeutic effect of these medications (around 15–19/14–15 mmHg), and there is no clear indication that knowledge of the genotype can influence drug choice in a clinically significant manner.

The exploration of pharmacogenetics of antihypertensive therapies has since reached the GWAS era. Thus far, pharmacogenetics influences on the efficacy of a diuretic (hydrochlorothiazide) have been shown with variants at the LYZ-FRS2-YEATS4 (Bonferroni corrected P=0.024) (89), PRKCA (P=3.3×10⁻⁷) (90) loci with allelic effects within the region of 3–8/2–4 mmHg, with the GNAS-EDN3 locus approaching genome-wide significance (P=5.5×10⁻⁸) (90). Both protein kinase Ca (PRKCA) and GNAS Complex Locus and endothelin 3, respectively (GNAS-EDN3) loci encode proteins involved in calcium signalling and vascular smooth muscle contraction, but the potential biological relevance of LYZ (lysozyme), FRS2 (fibroblast growth factor receptor substrate 2) or YEATS4 (YEATS domain containing 4) is currently unclear. There has also been a reported pharmacogenetic impact of the SLC25A31 rs201279313 deletion genotype influencing blood pressure response to β-blockers in a study limited to African Americans (P=2.5×10⁻⁸), with the LRRC15 locus approaching genome-wide significance (P=7.2×10⁻⁸). The relevance of both these genes in the blood pressure regulation or the pharmacokinetics/pharmacodynamics of β-blockers is unclear (91). However, as these studies only assessed the response to one drug class, it would not assist in decision making between different the use of different therapeutic drug classes. A following Genetic Epidemiology of Responses to Antihypertensives (GERA) study aim to identify SNPs with pharmacogenetic effects exhibiting opposite direction associations with BP response between diuretic and angiotensin II receptor blocker treatments, but the results were not replicated in an independent study, with none of the SNPs attaining genome-wide significance (92). A pharmacogenetics GWAS study randomly allocating patients to bisoprolol, losartan, HCTZ or amlodipine as monotherapy in a cross-over design initially demonstrated three SNPs (at the ACY3 gene) were significantly associated to BP response to bisoprolol, but none were successfully replicated (93).

Adverse drug reaction have a role in medicines non-adherence, which in turn contributes to suboptimal blood pressure management. Therefore, the ability to predict the likelihood of adverse drug events may be useful. The ACE inhibitor-induced cough is common, and often necessitates a change in drug class to an angiotensin receptor blocker. This adverse effect has been shown in variations in ABO haplotype (94,95), SLCO1B1 (96), KCNIP4 (97), BDKRB2 (94), NK2R (98) and the ACE insertion/deletion variant (99), although these variants were not detected in a recent pharmacogenetics GWAS (100). Thiazide-induced hyponatraemia is also common and can have severe consequences. This adverse reaction has been recently shown to be associated with 14 genetic regions, with further testing indicating a non-synonymous variation of solute carrier organic anion transporter family member 2a1 (SLCO2A1), also known as prostaglandin transporter, also showing a phenotype of intravascular volume expansion, free water reabsorption, urinary prostaglandin E2 excretion, and reduced excretion of serum chloride and antidiuretic hormone (101). Pharmacogenetic GWAS have also identified up to 6 genetic signals for hydrochlorothiazide-induced hyperuricaemia (102).

Despite these advances, pharmacogenetics in hypertension is still far from clinical practice, and requires comparison against successes elsewhere. Pharmacogenetics of predicting adverse drug events has had success with HLA-B*5701 screening for hypersensitivity to the anti-HIV-therapy, abacavir, where there is high predictive value and the ability to prevent a severe, life-threatening reaction (103). This has perhaps set an exceedingly high standard of impact that a pharmacogenetic test for adverse drug reactions should achieve. The antihypertensive pharmacogenetic studies thus far have only provided some mechanistical insights, but without the necessary predictive values and to influence the choice of antihypertensive drugs.

Our current understanding of pharmacogenetics is often complicated by datasets that includes polypharmacy (including non-cardiovascular medications), numerous
drugs and dosing ranges within each antihypertensive drug class, resulting in multiple confounding factors. To minimise these confounders, most pharmacogenetic GWAS so far have used subsets of randomized controlled trials comparing different classes of antihypertensive drugs, for which consenting subjects have subsequently been genotyped, for example the GenHAT study as a subset of the ALLHAT study (104). Furthermore, studies in pharmacogenetics still lag behind the large sample sizes of GWAS. In the context of clinically-predetermined guidelines for first-line (and even second- and third-line) drug choices (83), it may be difficult to obtain sufficient new data that would be able to compare pharmacogenetic effects. With this, the International Consortium for Antihypertensive Pharmacogenomics Studies (ICAPS) was formed in 2012 to increase the opportunities to discover and replicate genetic signatures of many different phenotypes related to antihypertensive treatment response. To date, no signals reach genome-wide significance for influencing the impact of diuretics on blood pressure (105). Alternatively, consortia such as the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium (http://www.chargeconsortium.com) have included observational studies within pharmacogenetics analyses, using longitudinal cohorts containing accurate medical records for drug exposure. Similarly, this has so far been unable to identify any genome-wide significant interactions from four antihypertensive therapy meta-analyses for cardiovascular outcomes (ACE inhibitor/angiotensin receptor blockers, β-blockers, calcium channel blockers or diuretics) (106).

While initial evidence being limited, there is still hope for pharmacogenetic studies to expand in sample sizes, potentially identifying genetic variants with contrasting associations and unique effects to different classes of antihypertensive drugs. There are still many barriers before being able to reach clinical application, which would also need to require the consideration of cost-effectiveness, particularly in the presence of only marginal gains.

**Summary**

In light of the largest cardiovascular GWAS to date, this review considered whether the knowledge of hypertension genomics has made an impact on clinical practice, and how it may do so in the future. Of the numerous loci and genes implicated in the pathophysiology of hypertension, \textit{UMOD} has shown promise as a new pharmacological target, and there is a strong enrichment of targets within the TGF-β pathway. In the future, there may be a role for combining GWAS of other comorbidities or cardiovascular endpoints to identify targets that may have a dual effect, where \textit{CPS1}, \textit{MTNR1B} and \textit{ABO} may be the best options highlighted. The development of large DNA biobanks with dense phenotypic information would also allow future studies in the form of phenome-wide association studies (PheWAS), where well-curated electronic health records would allow investigators to use a variety of input functions such as single/multiple SNPs, drug exposure or predicted gene expression to probe broader phenotypes (107). GxE studies may also be important in this aspect, with \textit{CASP4} appearing as an interesting candidate gene for salt-sensitivity. Pharmacogenetic and genetic risk score studies have also reveal some exciting mechanistical insights, but clinical application currently remains a distant prospect. With an expansion in the sample sizes of studies, the combination of multiple genetic signals may be sufficient to achieve clinical significance in the future. Should the technological costs of assessing panels of genetic variants decrease, there may still be cost-effectiveness in these measures.

**Acknowledgements**

None.

**Footnote**

\textit{Conflicts of Interest:} The authors have no conflicts of interest to declare.

**References**


32. Comai S, Ochoa-Sanchez R, Gobbi G. Sleep-wake characterization of double MT(1)/MT(2) receptor knockout mice and comparison with MT(1) and MT(2) receptor knockout mice. Behav Brain Res 2013;243:231-8.
55. Jenkins PV, O’Donnell JS. ABO blood group determinates plasma von Willebrand factor levels: a biologic function
after all? Transfusion 2006;46:1836-44.


83. NICE. Hypertension in adults: diagnosis and management Clinical guideline [CG127]. Available online: https://www.nice.org.uk/guidance/cg127


Cite this article as: Ng FL, Warren HR, Caulfield MJ. Hypertension genomics and cardiovascular prevention. Ann Transl Med 2018;6(15):291. doi: 10.21037/atm.2018.06.34